Uncategorized

Pain drugmaker Latigo outlines plans to go public

The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.

​Read More

Published

on

The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.

​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version